Today and Tomorrow: Managing Resistance in Heavily ART-Experienced People with HIV
Premiere Date: Friday, December 9, 2022This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, December 9, 2023
Note: Credit Is No Longer Available
 | David Alain Wohl, MD (Moderator) Professor of Medicine Institute of Global Health and Infectious Diseases Site Leader, Global Infectious Diseases Clinical Trials Unit, Chapel Hill Site The University of North Carolina (UNC) at Chapel Hill School of Medicine Chapel Hill, NC |
 | Sorana Segal-Maurer, MD Director, The Dr. James J. Rahal Jr. Division of Infectious Diseases NewYork-Presbyterian Queens Professor of Clinical Medicine Weill Cornell Medical College Cornell University New York, NY |
The use of antiretroviral (ARV) medication therapies has led to successful treatment for many patients with HIV. However, antiretroviral therapy (ART) resistance and medication adherence problems can reduce the chances of treatment success.1,2 Health care professionals (HCPs) need up-to-date education on the causes of ART resistance and non-adherence for patients who are treatment-experienced, as well as the treatment alternatives available including new ARV therapies with varying mechanisms of delivery (e.g., oral vs. injections). With this education, HCPs will be better prepared to treat patients with HIV who are treatment-experienced, reducing or mitigating the problems of ART treatment resistance and medication non-adherence.
In this CMEOCast podcast, expert faculty will present the latest information on the causes of ART resistance and medication non-adherence in patients with HIV and discuss the latest medication therapies that may prevent or counter treatment resistance and non-adherence, especially in patients who are treatment-experienced.
At the end of this CE activity, participants should be able to:
- Identify the etiology of ARV treatment resistance to improve HCPs’ competence in assessing and managing HIV in individuals who are heavily treatment experienced.
- Apply efficacy and safety data for current and new ARV treatments that minimize risk of treatment resistance in treatment-experienced patients with HIV.
- Evaluate efficacy and safety data for new and emerging long-acting oral and injectable ART regimens for heavily treatment-experienced people with HIV, including individuals with ARV resistance.
Supported by an educational grant from Gilead Sciences, Inc. This educational activity is supported by an independent educational grant from ViiV Healthcare.
ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
PAs, NPs, nurses, pharmacists, primary care physicians and physicians specializing in infectious disease
ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Royal College MOC
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Wohl reports the following financial relationships:
Advisory Board: Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Theratechnologies Inc.; and ViiV Healthcare
Consultant: Gilead Sciences, Inc.; and Janssen Pharmaceuticals, Inc.
Grants and Research Support: Eli Lilly and Company; Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare
Dr. Segal-Mauer reports the following financial relationships:
Consultant: Gilead Sciences, Inc. and Janssen Pharmaceuticals, Inc.
Speakers Bureau: Gilead Sciences, Inc. and Janssen Pharmaceuticals, Inc.
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PD-094-120922-90
